CrossrefInfokarte
Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study
European Journal of Cancer · 2026-11 · 248 · 117039
DOI: 10.1016/j.ejca.2026.117039 ↗Abstract
Kein Abstract verfügbar.
EUVIMED